Description
IPO-33
IPO-33 It’scannabinoid and an indazole analog of JWH-167 IUPACname: 1-(1-Pentyl-1H-indazol-3-yl)-2-phenyl-ethanone Formula: C20H22N2O Purity:99,7% min
Appearance:white powder
IPO-33 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
IPO-33 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
IPO-33 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
IPO-33 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
IPO-33 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
The physiological and toxicological properties of this compound have not been tested. This product is intended for forensic and research applications.
